FCF yield spoločnosti Inhibrx
Aká je hodnota metriky FCF yield spoločnosti Inhibrx?
Hodnota metriky FCF yield spoločnosti Inhibrx, Inc. je -18.58%
Aká je definícia metriky FCF yield?
Free cash flow yield (FCF yield) is a financial ratio that compares the free cash flow per share to the market value per share. The ratio is calculated by dividing free cash flow per share by the current share price.
ttm (trailing twelve months)
Free cash flow yield is a good measure of the company’s cash flow in respect to the company’s size. Larger companies tend to have a higher cash flow yield, but it’s not always the case. The higher the free cash flow yield, the more cash the company is generating that can be quickly accessed to satisfy its obligations. The lower the free cash flow yield, the more money investors are putting into the company with little result. The higher the ratio, the more attractive the investment is as it suggests that investors are paying less for each unit of free cash flow.
Free cash flow acts as an indicator of how capable a company is of repaying all of its obligations. It is a solid indicator of how financially stable a company is. It is calculated as:
Free cash flow yield = Free cash flow per share / market price per share
FCF yield spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Inhibrx
Čomu sa venuje spoločnosť Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Firmy s metrikou fcf yield podobnou spoločnosti Inhibrx
- Hodnota metriky FCF yield spoločnosti Defiance Silver je -18.63%
- Hodnota metriky FCF yield spoločnosti Ivanhoe Electric Inc je -18.61%
- Hodnota metriky FCF yield spoločnosti Thunderstruck Resources je -18.61%
- Hodnota metriky FCF yield spoločnosti Western Forest Products je -18.60%
- Hodnota metriky FCF yield spoločnosti PainChek je -18.60%
- Hodnota metriky FCF yield spoločnosti Holders Technology plc je -18.58%
- Hodnota metriky FCF yield spoločnosti Inhibrx je -18.58%
- Hodnota metriky FCF yield spoločnosti Sparq Corp je -18.57%
- Hodnota metriky FCF yield spoločnosti Maanshan Iron & Steel je -18.56%
- Hodnota metriky FCF yield spoločnosti genedrive plc je -18.56%
- Hodnota metriky FCF yield spoločnosti Kolibri Global Inc je -18.55%
- Hodnota metriky FCF yield spoločnosti American Well Corp je -18.54%
- Hodnota metriky FCF yield spoločnosti Enochian Biosciences Inc je -18.54%